Dermata Therapeutics (Dermata Therapeutics) Debt-to-Asset : 0.00 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Dermata Therapeutics Debt-to-Asset?

Dermata Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Dermata Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Dermata Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $5.18 Mil. Dermata Therapeutics's debt to asset for the quarter that ended in Mar. 2024 was 0.00.

Dermata Therapeutics Debt-to-Asset Historical Data

The historical data trend for Dermata Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dermata Therapeutics Debt-to-Asset Chart

Dermata Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

0.62

5.86

Dermata Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial													-	-	-	-	-

Competitive Comparison of Dermata Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, Dermata Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dermata Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dermata Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Dermata Therapeutics's Debt-to-Asset falls into.

Dermata Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Dermata Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	7.979
	=	0.00

Dermata Therapeutics's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	5.18
	=	0.00

Dermata Therapeutics (NAS:DRMAW) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Dermata Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Dermata Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Dermata Therapeutics (Dermata Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dermata Therapeutics Inc (NAS:DRMAW) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

DRMA:USA

Address

3525 Del Mar Heights Road, Suite No. 322, San Diego, CA, USA, 92130

Website

https://www.dermatarx.com

Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.